eligibility_summary
Include: ≥60, aggressive B‑cell lymphoma unfit for full‑dose R‑CHOP, PET‑measurable, biopsy available, no prior systemic therapy, ECOG≤2, ≥12‑wk expectancy, adequate organ function, HBV/HCV/HIV‑negative, no active COVID, contraception required. Exclude: other listed leukemias/lymphomas, active infection, neuropathy>G1, PML/CNS disease, recent malignancy, major cardiac/pulmonary/autoimmune disease, uncontrolled effusions/ILD, recent therapy/transplant, unresolved AEs, high‑dose steroids/immunosuppression, live vaccine, substance abuse, allergy to study drugs, pregnancy, or consent/legal issues.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm “chemotherapy-light” regimen (R-Pola-Glo) for untreated aggressive B‑cell lymphoma (DLBCL) in patients >60 ineligible for full‑dose R‑CHOP. Interventions and mechanisms: • Rituximab: chimeric anti‑CD20 monoclonal antibody (IgG1), depletes B cells via ADCC, complement activation, and apoptosis. • Glofitamab: CD20×CD3 bispecific IgG, engages T cells via CD3 to redirect cytotoxicity against CD20+ B cells. • Polatuzumab vedotin: antibody–drug conjugate targeting CD79b, internalization releases MMAE (microtubule inhibitor) causing mitotic arrest and apoptosis. • Obinutuzumab: glycoengineered type II anti‑CD20 monoclonal antibody, enhanced ADCC and direct cell death. Targets and pathways: malignant B cells expressing CD20 and CD79b, Fc-mediated effector functions (ADCC/complement), T‑cell activation via CD3, and B‑cell receptor complex component CD79b with downstream microtubule disruption.